Paysign, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

25 Mar 2026

PAYS

10-K: Paysign Reports Strong 2025 Growth, Driven by Pharma & Plasma

Paysign, Inc. (PAYS) reported significant revenue and net income growth in 2025, fueled by expansion in its pharmaceutical and plasma industry programs and the acquisition of Gamma Innovation LLC.

NASDAQ

26 Mar 2025

PAYS

Paysign, INC

10-K: Paysign Reports Strong Revenue Growth in 2024, Driven by Pharma and Plasma Segments

Paysign's 2024 10-K filing reveals a 23.5% increase in total revenue, fueled by significant growth in the pharma and plasma industries, alongside strategic investments in technology and compliance.

NASDAQ

27 Mar 2024

PAYS

Paysign, INC

10-K: Paysign Inc. Reports 24.3% Revenue Increase in 2023 Driven by Plasma and Pharma Growth

Paysign Inc. saw a significant 24.3% increase in revenue in 2023, primarily driven by growth in its plasma and pharmaceutical sectors.